Clinical Trial: Retinoblastoma Biomarker Study

Study Status: Active, not recruiting
Recruit Status: Active, not recruiting
Study Type: Observational

Official Title: Retinoblastoma Biomarker Study

Brief Summary: A series of 1,729 retinoblastoma (RB) patients were identified from medical records at hospital centers in Boston (1937-84) and New York (1914-84). The study cohort consists of the 1,604 patients who survived at least 1 year after RB diagnosis. Information was obtained from medical records and interviews conducted in 1987 and 1993. RB patients had a 30-fold excess risk of another cancer, and a 50% chance of developing a cancer if they survived to 50 years of age. Blood samples have been collected from 481 patients, and studies are underway to determine if certain mutations in the RB1 genes are associated with increased or decreased penetrance or with increased risk of subsequent cancer development. The study population in New York is being expanded currently to include patients treated since 1984, and their medical records are being abstracted. Blood samples will be collected from the newly identified patients who are returning to New York Hospital for a followup RB exam.

Detailed Summary: A series of 1,729 retinoblastoma (RB) patients were identified from medical records at hospital centers in Boston (1937-84) and New York (1914-84). The study cohort consists of the 1,604 patients who survived at least 1 year after RB diagnosis. Information was obtained from medical records and interviews conducted in 1987 and 1993. RB patients had a 30-fold excess risk of another cancer, and a 50% chance of developing a cancer if they survived to 50 years of age. Blood samples have been collected from 481 patients, and studies are underway to determine if certain mutations in the RB1 genes are associated with increased or decreased penetrance or with increased risk of subsequent cancer development. The study population in New York is being expanded currently to include patients treated since 1984, and their medical records are being abstracted. Blood samples will be collected from the newly identified patients who are returning to New York Hospital for a followup RB exam.
Sponsor: National Cancer Institute (NCI)

Current Primary Outcome:

Original Primary Outcome:

Current Secondary Outcome:

Original Secondary Outcome:

Information By: National Institutes of Health Clinical Center (CC)

Dates:
Date Received: June 19, 2006
Date Started: November 17, 1993
Date Completion:
Last Updated: April 20, 2017
Last Verified: November 29, 2016